APOA4

Across TCGA pan-cancer cohorts, APOA4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated APOA4 data layer compared with 18 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher APOA4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated APOA4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where APOA4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.792	0.389	<.001	76	view →
UCEC	DFS	Median	III,IV	0.424	1.000	.003	24	view →
PDAC	DFS	Tertile	All	0.535	0.319	.009	18	view →
LUAD	OS	Median	All	0.933	0.705	.027	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

APOA4–CCRCC (DFS)

Open the CCRCC breakdown →